Results 171 to 180 of about 402,660 (356)

Psychotropic medication use among community dwellers with and without Parkinson's disease – A nationwide cohort study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims We studied the prevalence of psychotropic use and psychotropic polypharmacy in persons with Parkinson's disease (PD) during a 10‐year follow‐up, because longitudinal studies on this topic are scarce although non‐motor symptoms of PD are often treated with psychotropics.
Noora Nieminen, Anna‐Maija Tolppanen, Valtteri Kaasinen, Marjaana Koponen, Sirpa Hartikainen   +4 more
wiley   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Neuronal differentiation and tissue engineering strategies for central neurous system injury repair

BMEMat, EarlyView.
This review outlines tissue engineering advances for central nervous system (CNS) injury treatment, focusing on three core components: seed cells, inductive factors, and scaffold materials, with evaluation of their respective strengths and limitations. Tissue engineering for CNS injury repair.
Zhuqing Xia, Jinghui Zhang, Na Ren, Shuping Wang, Congcong Zhang, Nik Ahmad Nizam Nik Malek, Wan Hairul Anuar Kamaruddin, Chao Liu, Chunhui Sun, Jingang Wang   +9 more
wiley   +1 more source

Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review).

International Journal of Molecular Medicine, 2018
Ji-dong Guo, Xin Zhao, Yang Li, Guang-Ren Li, Xiao-Liang Liu   +4 more
semanticscholar   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

A neuro‐behavioural model of neophobia

Biological Reviews, EarlyView.
ABSTRACT Fear can be defined as the internal neurological state that releases a repertoire of behaviours an animal performs to reduce the effect of an aversive factor. Neophobia, the fear of novelty, is a fundamental behavioural trait observed across a wide range of species from arthropods to humans.
Arik Dorfman, Aziz Subach, Inon Scharf
wiley   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Assessment of Abuse Potential‐Related Effects of Oral Dried Kratom Leaf Powder in Healthy Normal Participants Following Single and Multiple Daily Doses

Drug Testing and Analysis, EarlyView.
In a randomized, double‐blind, placebo‐controlled study of oral dried kratom leaf powder in healthy kratom‐naive adults, no participants met the clinically meaningful opioid withdrawal threshold; abuse‐related treatment‐emergent adverse events occurred more frequently at higher doses but were generally mild and resolved without sequelae; and no serious
Marion Coe, Marilyn Huestis, Daniel Wang, Thomas Hudzik, John Bothmer, Jack Henningfield   +5 more
wiley   +1 more source

Daily Ovarian Hormone Exposure and Loss of Control Eating in Adolescent Girls: A Stage 2 Registered Report

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective This Stage 2 Registered Report examined (1) the main effects and interaction of within‐person daily associations between ovarian hormones (i.e., estrogen, progesterone) and loss of control eating (LOCE), and (2) the within‐person mediating roles of food‐related reward anticipation and response inhibition. Methods Adolescent girls (n =
Tyler B. Mason, Jeremy C. Morales, Kathryn E. Smith, Genevieve F. Dunton, Raina D. Pang   +4 more
wiley   +1 more source